IP Library Granted Patent US 7,772,357
Granted Patent B2
US 7,772,357 · App. 12/559,162 · Granted Aug 10, 2010

Hydrolytically degradable polymers and hydrogels made therefrom

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,357
App. No.
12/559,162
Granted
Aug 10, 2010
Kind
B2
Abstract

A water soluble polymer comprising multiple degradable carbonate linkages in a backbone and, for each carbonate linkage in the backbone, an oligomer linked thereto by the carbonate linkage, wherein the oligomer is branched.

Claims (12)

1. A conjugate of a biologically active agent and a polyalkylene oxide-based water soluble polymer in activated form, wherein the polyalkylene oxide-based water soluble polymer comprises multiple carbonate linkages in a backbone and, for each carbonate linkage in the backbone, an oligomer linked thereto by the carbonate linkage, wherein the oligomer is branched and, prior to being linked by the carbonate linkage, has the formula:

R 3 [O—(—CHR 1 CH 2 —O—) n —] m H

where R 3 is a core branching moiety, R 1 is H, (n) can range from 2 to 2000, and m is at least 3.

2. The conjugate of claim 1 , wherein the polyalkylene oxide-based water soluble polymer in activated form corresponds to the polyalkylene oxide-based water soluble polymer having at least one end group selected from the group consisting of acryloyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl.

3. The conjugate of claim 1 , wherein the polyalkylene oxide-based water soluble polymer in activated form corresponds to the polyalkylene oxide-based water soluble polymer having at least one end group selected from the group consisting of N-succinimidyl, 1-benzotriazolyl and p-nitrophenyl.

4. The conjugate of claim 3 , wherein the end group is N-succinimidyl.

5. The conjugate of claim 3 , wherein the end group is 1-benzotriazolyl.

6. The conjugate of claim 3 , wherein the end group is p-nitrophenyl.

7. The conjugate of claim 1 , wherein the biologically active agent is a peptide.

8. The conjugate of claim 1 , wherein the biologically active agent is a protein.

9. The conjugate of claim 1 , wherein (n) is 5 to 500.

10. The conjugate of claim 1 , wherein (n) is 10 to 50.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →